Sublinguial allergen extract immunotherapy in a rush pattern to reach the maintainance faster

N. Pandey, S. Kole, S. P. Singh, S. Gupta Bhattacharya, S. Kumar, S. Bibhore (Kolkata, Purnia, Kol, Panchkulla, India)

Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Session: Allergen immunotherapy and anti-immunoglobulin E
Session type: Poster Discussion
Number: 262
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Pandey, S. Kole, S. P. Singh, S. Gupta Bhattacharya, S. Kumar, S. Bibhore (Kolkata, Purnia, Kol, Panchkulla, India). Sublinguial allergen extract immunotherapy in a rush pattern to reach the maintainance faster. Eur Respir J 2011; 38: Suppl. 55, 262

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Specific immunotherapy with high dose grass allergen tablets was safe in grass pollen induced asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 134s
Year: 2005

Bronchial challenge with flour: early response is dependent on the dose of activated allergen inhaled
Source: Eur Respir J 2002; 20: 409-416
Year: 2002



Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

Compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012

Mild asthmatic patients consistently respond to natural, low dose, allergen challenge in an EEC
Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases
Year: 2011

Reduced late asthmatic response by repeated low-dose allergen exposure
Source: Eur Respir J 2001; 17: 872-880
Year: 2001



Specific allergen immunotherapy might be safer than previous assumed when performed correct
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 107s
Year: 2002

Allergen specific immunotherapy efficacy in children with pollen-food allergy syndrome and different IgE profiles to recombinant component-resolved allergens.
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

Effect of allergen-specific immunotherapy on platelet secretory activity in patients with house-dust mite allergy
Source: Eur Respir J 2007; 30: Suppl. 51, 369s
Year: 2007

Effect of allergen particle size on inflammatory and cellular profile after mite bronchial challenge test
Source: Eur Respir J 2006; 28: Suppl. 50, 593s
Year: 2006

Evaluation and efficacy of allergen immunotherapy in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 399s
Year: 2005

The inhaled allergen challenge test
Source: Short video discussion 2022
Year: 2022

Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021


The immune characteristics of inhalational tolerance induced by prolonged allergen exposure
Source: Annual Congress 2007 - Regulation of allergic airway inflammation in animal models of asthma
Year: 2007


Optimum dosing regimen for repeated low dose allergen challenge in chronic allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 103s
Year: 2001

Evaluation of nasal response to birch allergen in ALYATEC EEC as compared to NPT
Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials
Year: 2021


Investigation of gene expression in relation to omalizumab treatment and peanut oral immunotherapy
Source: Virtual Congress 2021 – Biomarkers and risk factors in childhood asthma
Year: 2021


House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma
Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Year: 2020


Identification of late asthmatic reactions following specific inhalation challenge
Source: International Congress 2019 – Airway and parenchymal diseases in occupational and environmental lung diseases
Year: 2019